About Us
Our Story
Founded in 2023, The Lilly and Blair Foundation was born out of a serendipitous meeting between two families navigating a new normal after receiving the same devastating diagnosis for their little girls. Since then, our team has worked tirelessly as we continue to participate in numerous studies, meet with leading researchers and doctors, connect with other families, and educate our communities. Most importantly, we continue to push the boundaries of hope and research to find a cure or treatment for all children impacted by de novo SPG4. Please join our fight as we work to rewrite the future for these incredible children.
July 2021 - Received diagnoses
August 2021 - Provided blood and DNA samples for NIH study
December 2021 - Enrolled in Natural History Study at Boston Children’s Hospital
April 2022 - Participated in the Inaugural Scientific Symposium on De Novo SPG4 (view the parent perspectives from Chris and Katie)
January 2023 - Formed The Lilly and Blair Foundation
March 2023 - Featured in The Washington Post
June 2023 - Hosted our first annual Golf Tournament and Dinner (view photos and remarks) and led the Childhood-Onset session at the SPF conference
September 2023 - Received 501(c)(3) status
December 2024 - Partnered with NIH to host the Second Scientific Symposium on De Novo SPG4
February 2024 - Interviewed by The Washington Post Live alongside experts from the FDA and Cure Rare Disease
May 2024 - Fully funded the Baas Lab at Drexel University’s project to develop a new mouse model that will be used to help determine the underlying biology of the disease and test new therapies including ASOs and gene therapy
May 2024 - Launched monthly virtual support group meetings with other SPAST c.1496G>A, p.Arg499His families
June 2024 - Hosted our second annual Golf Tournament and Dinner (view photos and remarks)
July 2024 - In collaboration with the Cure SPG4 Foundation and the Laidlaw family, The Lilly and Blair Foundation funded the first 3 aims of the AAV9 Vector Gene Therapy Project for SPG4
December 2024 - Partnering with Boston Children’s Hospital to host the 3rd Annual Scientific Symposium on SPG4
The Faces of Childhood-Onset, De Novo SPG4
-
Blair
Blair (often referred to as “Blair Bear”) lights up every room she enters and can change the course of any bad day with her brilliant smile. Blair loves to explore nature and she is an extremely affectionate child who loves stuffed animals, particularly her lifelong best friend “panda bear”. Blair is extremely empathetic and a relentless hard worker, serving as a role model to all she encounters who can clearly see the challenges she herself faces in daily life. Even at 6 years old, and despite hours of therapy each day and weeks of intensive therapy each year, Blair has never been able to walk independently without support and her wheelchair providers her main source of mobility.
-
Lilly
Lilly is a determined, opinionated and kind little girl. She has never met someone or something she doesn't want to "help" and she loves dancing and singing, her stuffed animals, baking, and her brother, cousins and friends. At just 5 years old, she is mature beyond her years and endures interventions, medications and endless therapies with a resilience far beyond her age. Lilly primarily crawls around the home, uses a walker at school and relies on her wheelchair more and more for longer distances. She navigates life with a smile on her face and an endless curiosity about the world around her, even when she has to rely on someone else to help her experience the life most of us live without second thought.
-
Max
Max is a happy and silly 3-year-old boy who has shown global developmental delays since birth. He was officially diagnosed with de novo SPG4 at age 2.5. He has worked hard strengthening his muscles in physical therapy since he was 4 months old and hopes to gain enough strength to walk on his own one day. Max is learning to use his wheelchair outside of the home, and refuses to let his disability get in the way of playing with others. Max loves to play with cars and trucks, read books, and scare his friends by pretending he’s a dinosaur. He has a huge smile and gives tight hugs and sweet kisses to his friends and family.
-
Sam
By 10 months of age, Sam’s parents noticed developmental delays. After consultations with neurologists and extensive tested, he was initially believed to have cerebral palsy. In 2021, genetic testing confirmed de novo SPG4. Sam, now 12, experiences increasing leg spasticity and low muscle tone, as well as impacts to his speech. He has received various treatments, including a baclofen pump. Despite being mostly wheelchair-bound, Sam enjoys therapy, video games, fishing, and spending time with his friends and family. He remains a happy, compassionate, and determined boy who smiles through both good and challenging times.
Medical Advisory Board
-
Darius Ebrahimi-Fakhari, MD, PhD
DIRECTOR, MOVEMENT DISORDERS PROGRAM AND ATTENDING, DEPARTMENT OF NEUROLOGY, BOSTON CHILDREN’S HOSPITAL; ASSISTANT PROFESSOR OF NEUROLOGY, HARVARD MEDICAL SCHOOL
Dr. Ebrahimi-Fakhari is a child neurologist and neuroscientist with special expertise in childhood-onset neurogenetic, neurodegenerative, and movement disorders. His translational research includes The Registry and Natural History Study for Early-Onset Hereditary Spastic Paraplegia.
-
Ariane Soldatos, MD, MPH
DIRECTOR, PEDIATRIC NEUROLOGY CONSULTATION SERVICE, NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) AND PHYSICIAN SCIENTISTS, UNDIAGNOSED DISEASES PROGRAM, NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI), NATIONAL INSTITUTES OF HEALTH (NIH)
Dr. Soldatos' research interests include genomics and clinical trials for rare diseases. She is associate investigator on first-in-human clinical trials including gene therapy for rare childhood neurodegenerative diseases. -
Matthew Elrick, MD, PhD
ASSISTANT PROFESSOR OF NEUROLOGY, THE JOHNS HOPKINS HOSPITAL.
Dr. Elrick specializes in the care of children with neuromuscular disorders, and EMG studies in children and adults. He has special interests in genetic neuromuscular and neurodegenerative disorders and Acute Flaccid Myelitis.
Scott Chilson
Jay Coonan
Board of Directors
Katie Gregg
Chris Lorek
Stephanie Lorek
Michael Gregg
Industry Partners
The Lilly and Blair Foundation is proud to be part of the NORD’ RareAction Network and the Global Genes Advocacy Alliance, both of which advocate for equitable access to timely diagnosis, treatment, and care for rare diseases. Through these networks, we work to raise awareness, provide community support, advance research, and address the specific needs of individuals affected by rare diseases worldwide, aiming to improve outcomes and quality of life on a global scale.
Together We Can
Time is not on our side, but we hope you will be.